Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTG 384: Initial Antiretroviral Therapy Strategies
NCT00000919Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of didanosine, stavudine, efavirenz, nelfinavir, lamivudine and 1 more in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Time to failure of the second antiretroviral regimen. Status: completed.
02
Drugs
didanosinestavudineefavirenznelfinavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000919.